PMID- 25217622
OWN - NLM
STAT- MEDLINE
DCOM- 20160322
LR  - 20141124
IS  - 1569-9285 (Electronic)
IS  - 1569-9285 (Linking)
VI  - 19
IP  - 6
DP  - 2014 Dec
TI  - Preoperative risk factors of medium-term mitral valve repair outcome.
PG  - 946-54
LID - 10.1093/icvts/ivu294 [doi]
AB  - OBJECTIVES: This study aimed to evaluate risk factors that affect mitral valve 
      (MV) repair outcomes. METHODS: From 2002 to 2012, 580 consecutive patients with 
      mitral regurgitation (MR) underwent MV repair. Of the total number of patients, 
      48.9% were found to be in New York Heart Association (NYHA) Class III or IV. 
      Anterior, posterior and bileaflet prolapse was present in 34.8, 47.6 and 17.6% of 
      patients, respectively. Atrial fibrillation (AF) was found in 29.7% of patients. 
      The mean follow-up was 5.3 +/- 2.6 years. RESULTS: There were eight early and 14 
      late deaths. NYHA Class III/IV, left ventricular ejection fraction </=50%, systolic 
      pulmonary artery pressure >/=50 mmHg, AF and low cardiac output syndrome with 
      extracorporeal membrane oxygen were independent predictors of early mortality. 
      AF, NYHA Class III/IV, left ventricular end-systolic diameter >/=40 mm and systolic 
      pulmonary artery pressure >/=50 mmHg remained predictors of late mortality. At 5 
      years, the rate of survival, freedom from reoperation and recurrent moderate to 
      severe MR was 99.0 +/- 0.6 97.2 +/- 0.8 and 93.3 +/- 1.2%, respectively. Anterior 
      leaflet involvement was predictive of reoperation and recurrent moderate to 
      severe MR. In patients with a moderate tricuspid regurgitation (TR) and annulus 
      <40 mm, the degree of TR during follow-up was worse with right ventricular 
      dilatation. CONCLUSIONS: MV repair should be performed before the deterioration 
      of ventricular function, development of pulmonary hypertension and AF occurrence. 
      The pathophysiology of MR affects MV repair durability, while concomitant 
      tricuspid annuloplasty should be considered in patients with moderate TR despite 
      annular dilatation.
CI  - (c) The Author 2014. Published by Oxford University Press on behalf of the European 
      Association for Cardio-Thoracic Surgery. All rights reserved.
FAU - Wang, Jiangang
AU  - Wang J
AD  - Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing, China wangjiangang7545@126.com.
FAU - Han, Jie
AU  - Han J
AD  - Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing, China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing, China.
FAU - Xu, Chunlei
AU  - Xu C
AD  - Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing, China.
FAU - Jiao, Yuqing
AU  - Jiao Y
AD  - Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing, China.
FAU - Yang, Bo
AU  - Yang B
AD  - University of Michigan Cardiovascular Center, University of Michigan, Ann Arbor, 
      MI, USA.
FAU - Meng, Xu
AU  - Meng X
AD  - Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical 
      University, Beijing, China.
FAU - Bolling, Steven F
AU  - Bolling SF
AD  - University of Michigan Cardiovascular Center, University of Michigan, Ann Arbor, 
      MI, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140912
PL  - England
TA  - Interact Cardiovasc Thorac Surg
JT  - Interactive cardiovascular and thoracic surgery
JID - 101158399
SB  - IM
CIN - Interact Cardiovasc Thorac Surg. 2014 Dec;19(6):954. PMID: 25417218
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/diagnosis/physiopathology
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Hemodynamics
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve/physiopathology/*surgery
MH  - *Mitral Valve Annuloplasty/adverse effects/mortality
MH  - Mitral Valve Insufficiency/diagnosis/mortality/physiopathology/*surgery
MH  - Mitral Valve Prolapse/diagnosis/mortality/physiopathology/*surgery
MH  - Proportional Hazards Models
MH  - Recurrence
MH  - Reoperation
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
MH  - Tricuspid Valve/physiopathology/surgery
MH  - Tricuspid Valve Insufficiency/diagnosis/physiopathology/surgery
MH  - Young Adult
OTO - NOTNLM
OT  - Atrial fibrillation
OT  - Mitral regurgitation
OT  - Mitral valve
OT  - Mitral valve repair
OT  - Tricuspid valve
EDAT- 2014/09/14 06:00
MHDA- 2016/03/24 06:00
CRDT- 2014/09/14 06:00
PHST- 2014/09/14 06:00 [entrez]
PHST- 2014/09/14 06:00 [pubmed]
PHST- 2016/03/24 06:00 [medline]
AID - ivu294 [pii]
AID - 10.1093/icvts/ivu294 [doi]
PST - ppublish
SO  - Interact Cardiovasc Thorac Surg. 2014 Dec;19(6):946-54. doi: 
      10.1093/icvts/ivu294. Epub 2014 Sep 12.